Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Mucociliary ClearanceCompleted with results Location: USA

    Phase 3 study of inhaled mannitol in adults with cystic fibrosis , protocol number DPM-CF-303 NCT02134353

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the inhaled drug mannitol and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirements

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      6

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia - QLD

    A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects , protocol number FDL169-2015-04 NCT03093714

    A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation

    • Age:

      18 Years to 85 Years

    • Mutation(s):

      Homozygous for the F508del-CFTR mutation.

    • FEV1% Predicted:

      (FEV1) >40% of predicted normal for age, sex and height.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Multicentre

    Saline Hypertonic in pre-schoolers + CT (SHIP-CT) , protocol number SHP002 NCT02950883

    The purpose of this study is to assess whether inhalation of 7% hypertonic saline (HS) twice daily for 48 weeks reduces structural lung disease as assessed by computed tomography (CT) in comparison with inhalation of 0.9% isotonic saline (IS) in preschool children (ages 3 to 6) with cystic fibrosis.

    • Age:

      3-5 years

    • Mutation(s):

      A documented genotype with two disease-causing mutations in the CFTR gene

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants , protocol number FDL176-2016-01 NCT03173573

    This is a 5-part study. Part 1 is a double blind, placebo-controlled, dose escalation, first-in-human study to assess the safety, tolerability and PK profiles following single oral administration of FDL176 to healthy male participants. Part 2 is a single dose, open-label study in healthy male participants to determine the effect of food on the PK profile of FDL176. Part 3 is a single dose, double blind, placebo-controlled study in healthy female participants to assess the PK, safety and tolerability profiles of FDL176. Part 4 is a randomised, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability and PK profiles following multiple oral administrations of FDL176 to healthy male and female participants. Part 5 is a single dose, open-label study in male and female participants with CF to determine the PK profile of FDL176.

    • Age:

      18 Years to 55 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA & Australia

    Phase 3 study of Ataluren in people with CF who have a nonsense mutation and are not taking aminoglycosides. , protocol number PTC124-GD-021-CF NCT02139306

    This study is taking place at multiple care centers across the U.S. It looked at the effectiveness and safety of the oral drug ataluren in people with CF who have a nonsense mutation of cystic fibrosis. This study used a placebo control.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      60 to 90%

    • Number of Visits:

      10

    • Length of Participation:

      56 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Multiple care centres across the US

    Cohort 3 of a study to evaluate inhaled QBW276 in adults with CF , protocol number Novartis QBW276 - Cohort 3

    This randomized, placebo-controlledstudy is taking place at multiple care centers across the US. This study will look at the safety, effectiveness and tolerability of the inhaled drug QBW276.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      15

    • Length of Participation:

      3 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US & Australia

    Phase 1/2 Study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis. , protocol number NCT03227471 VX16-445-001

    This study is taking place at multiple care centres across the US and Australia. It will look at the safety and effectiveness of the drug VX-445.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      6

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US & Australia

    A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation , protocol number NCT02565914 VX14-661-110

    This is a Phase 3, multicenter, open-label, 2-part rollover study in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation and who participated in Studies NCT02070744, NCT02347657, NCT02516410, NCT02392234, NCT02412111, and NCT02508207. The study is designed to evaluate the safety and efficacy of long term treatment of VX-661 in combination with ivacaftor.

    • Age:

      12 years and older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    A Phase 3 multi-centre randomised placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis (COMBATCF). , protocol number ACTRN12610001072000 NCT01270074

    The general aim of this project is to conduct a randomized double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The primary outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.

    • Age:

      6 Weeks to 6 Months

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Multicentre

    A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation , protocol number GLPG2222-CL-201 NCT03045523

    This clinical study is a phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate two doses of orally administered GLPG2222 in adult subjects with a confirmed diagnosis of CF harbouring one F508del CFTR mutation and a second gating (class III) mutation and on stable treatment with ivacaftor. Up to 35 evaluable subjects are planned to be included in the study. Eligible subjects must be on stable treatment with physician prescribed ivacaftor (Kalydeco®) for at least 28 days at the baseline visit. They will be randomized in a 2:2:1 ratio to receive one of two active doses of GLPG2222 (150 mg q.d. or 300 mg q.d.) or placebo q.d. administered for 29 days. Subjects will be in the study for a minimum of 6 weeks and a maximum of 10 weeks, from screening until the follow-up visit.

    • Age:

      18 years and older

    • Mutation(s):

      One F508del mutation on one allele in the CFTR gene, a gating (class III) mutation (one of the following: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R) on the 2nd allele in the

    • FEV1% Predicted:

      (FEV1) ≥ 40% of predicted normal for age, gender and height at screening

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 1-10 (of 142)
     |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|